Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MGV354 ophthalmic suspension
MGV354 · 1 trial · 2 indications
IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and reported in mmHg. Diurnal IOP was defined as the average of the five time points measured (8 AM, 10 AM, noon, 4 PM, and 8 PM). Baseline diurnal IOP was the average of IOP measurements obtained at the 2 eligibility visits. Change from baseline was calculated by taking the change at each time point from baseline to Day 8 and averaging the available changes. A more negative change from baseline indicates a greater improvement, i.e., a reduction of IOP. Only one eye (study eye) contributed to the analysis.
IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and reported in mmHg. Baseline IOP was the average of IOP measurements obtained at the 2 eligibility visits. Change from baseline was calculated by taking the change at each time point from baseline to Day 8. A more negative change from baseline indicates a greater improvement, i.e., a reduction of IOP. Only one eye (study eye) contributed to the analysis.
| Arm | Type | Description |
|---|---|---|
| MGV354 | EXPERIMENTAL | Part 3: MGV354 ophthalmic suspension, 1 drop in both eyes once per day for 7 days |
| Placebo | PLACEBO_COMPARATOR | Part 3: MGV354 placebo, 1 drop in both eyes once per day for 7 days |
| Name | Type | Description |
|---|---|---|
| MGV354 ophthalmic suspension | DRUG | - |
| MGV354 placebo | DRUG | Inactive ingredients used as placebo comparator |
Inclusion Criteria: * Documented informed consent. * Part 1: 18 to 70 years of age; * Parts 2 and 3: 18 years of age or older; * Able to communicate well with the investigator and understand and comply with the requirements of the study; * Body Mass Index (BMI) between 18 and 39; * In case of conta...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| SpyGlass Pharma, Inc. | SGP | 5 | PHASE3 | Bimatoprost System, BIM-DRS |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE3 | Bimatoprost ophthalmic solution |
| AbbVie, Inc. | ABBV | 1 | PHASE1 | AGN-193408 |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE1 | REGN22530 |
| Glaukos Corp | GKOS | 2 | - | Travoprost |
MGV354 is an investigational small molecule developed by Alcon Inc. (ticker ALC) as an ophthalmic suspension. It was studied for ocular hypertension and open-angle glaucoma, conditions in which pressure inside the eye is elevated. It is a Phase 1 candidate and is not an approved therapy.
MGV354 was studied for ocular hypertension and open-angle glaucoma, eye conditions characterized by elevated intraocular pressure. It was administered as an ophthalmic suspension. Development reached Phase 1, and the compound remains investigational rather than an approved treatment for these indications.
MGV354 is developed by Alcon Inc., which trades under the ticker ALC. Alcon is the sponsor behind the ophthalmic suspension program for ocular hypertension and open-angle glaucoma. The asset is an investigational small molecule that has completed a Phase 1 study.
MGV354 is in Phase 1 development. One Phase 1 trial has been completed, and no trials are currently active. Because it is investigational, MGV354 is not an approved product for ocular hypertension or open-angle glaucoma, and further clinical development would be required before any regulatory review.
MGV354 has been evaluated in one completed Phase 1 trial, NCT02743780, titled A Three Part Study of MGV354 in Ocular Hypertension or Glaucoma. The randomized, double-blind, placebo-controlled study enrolled 191 participants aged 18 years and older, including healthy volunteers, across ocular hypertension and open-angle glaucoma.
Yes. MGV354 ophthalmic suspension is the same asset as MGV354, referring to the formulation used in its clinical program. Alcon Inc. (ticker ALC) developed this small molecule as an eye drop suspension for ocular hypertension and open-angle glaucoma, and it completed a Phase 1 study.